IOB - Delayed Quote USD

0HD2.IL,0P0001H9AM,281 (0HD2.IL)

235.07

-1.93

(-0.81%)

At close: July 23 at 9:00:00 PM GMT+1

High Growth Tech Stocks In US With Potential For Expansion

The United States market is currently experiencing a mixed performance with major indexes such as the Dow Jones and S&P 500 showing modest gains, while the tech-heavy Nasdaq Composite has seen slight declines amid fluctuating trade policies and tariff exemptions. In this dynamic environment, identifying high growth tech stocks with potential for expansion requires careful consideration of factors such as innovation, market adaptability, and resilience to external economic pressures.

Simply Wall St. 2 days ago

ALNY

ASND

NTRA
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Political pressure and persistently high interest rates have some wondering if the industry’s model is broken.

The Wall Street Journal 5 days ago

ALNY

GILD

LLY
Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden panic on Wall Street has increased worries about a full-blown recession hitting in the near future. According to USA Today, several big banks are putting the chance of a recession at 40% or higher. Only time will tell if we dip into recession. For now, worried investors are seeking ‘recession-proof’ stocks to shore up their portfolios. The biopharma team at

TipRanks 6 days ago

ALNY

AXSM
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

CAMBRIDGE, Mass., April 01, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET.

Business Wire 15 days ago

ALNY
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip

Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its leadership in RNAi therapeutics. Despite broader market declines due to renewed tariff concerns impacting sectors like auto, Alnylam's R&D advancements and robust earnings report, showing nearly 35% growth in revenue, likely contributed to the stock's positive performance. The company's strategic...

Simply Wall St. 18 days ago

ALNY
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025

CAMBRIDGE, Mass., March 29, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today’s patients. Data were presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) held in Chicago, Illinois. Th

Business Wire 18 days ago

ALNY
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision

Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 17% price increase over the past week, likely influenced by its recent announcements and market trends. The company's R&D progress showcase on February 25, featuring innovations like Nucresiran's high TTR knockdown capability and Vutrisiran's impending FDA decision, highlighted its strong pipeline, potentially boosting investor confidence. Additionally, the retirement announcement of co-founder Dr. Phillip A. Sharp on March 5 may have emphasized a...

Simply Wall St. 24 days ago

ALNY
Alnylam price target raised to $338 from $300 at Scotiabank

Scotiabank raised the firm’s price target on Alnylam (ALNY) to $338 from $300 and keeps an Outperform rating on the shares. The firm expects Amvuttra, the first transthyretin silencer to enter the market for the treatment of transthyretin amyloid cardiomyopathy, to see impressive uptake among the first-line setting given its unique mechanism of action, the analyst tells investors. The drug’s launch, however, will likely not gain momentum until 2H of 2025, the firm adds. Published first on TheFly

TipRanks 25 days ago

ALNY
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio

Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.

Investor's Business Daily 26 days ago

BBIO

PFE

ALNY
Alnylam Stock Jumps After the FDA Approves Its Heart Drug

Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger population of patients with a genetic heart condition. The FDA cleared the drug after the close on Thursday, allowing Alnylam to compete against Pfizer and BridgeBio to treat patients with the disease. Alnylam has long been a favorite among biotech investors, but the company hasn’t yet shown it can transition from being a R&D innovator to a sustainable business.

The Wall Street Journal 26 days ago

ALNY

BBIO

PFE
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

CAMBRIDGE, Mass., March 20, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure

Business Wire 27 days ago

ALNY
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

CAMBRIDGE, Mass., March 11, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 3:00 pm ET.

Business Wire last month

ALNY
Dr. Phillip A. Sharp Retirement From Alnylam Pharmaceuticals (NasdaqGS:ALNY) Board Announced

Alnylam Pharmaceuticals (NasdaqGS:ALNY)'s share price increased by 2.2% last week, a rise that coincided with the announcement of Dr. Phillip A. Sharp's upcoming retirement from the Board of Directors. Dr. Sharp, a co-founder and long-standing advisor, significantly impacted the company's trajectory. Despite broader market challenges, such as tariff-related sell-offs that caused the Nasdaq Composite to decline by 1.1%, Alnylam maintained resilient performance. The general market saw a 1.9%...

Simply Wall St. last month

ALNY
High Growth Tech Stocks Leading The US Market

Over the last 7 days, the United States market has dropped 1.9%, yet over the longer term, it has risen by 14% in the last year with earnings forecasted to grow by 14% annually. In this context of fluctuating short-term performance and promising long-term growth, identifying high growth tech stocks that demonstrate strong innovation and adaptability can be crucial for investors looking to capitalize on emerging opportunities within the US market.

Simply Wall St. last month

ALNY

NTNX

ORGO
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

CAMBRIDGE, Mass., March 05, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company’s Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board.

Business Wire last month

ALNY
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

CAMBRIDGE, Mass., February 25, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D progress and platform innovation, including updates on multiple near- and mid-stage potentially transformative therapies that represent blockbuster opportunities as its pipeline rapidly expands across multiple therapeutic areas.

Business Wire last month

ALNY
Alnylam Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Alnylam Pharmaceuticals ( NASDAQ:ALNY ) Full Year 2024 Results Key Financial Results Revenue: US$2.25b (up 23% from FY...

Simply Wall St. last month

ALNY
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

CAMBRIDGE, Mass., February 13, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and reviewed recent business highlights.

Business Wire 2 months ago

ALNY
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results

CAMBRIDGE, Mass., January 30, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open.

Business Wire 2 months ago

ALNY
Exploring Three High Growth Tech Stocks In The United States

The United States market has shown robust performance recently, climbing 3.0% in the last week and achieving a 25% increase over the past year, with earnings expected to grow by 15% annually. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability aligned with these positive market trends.

Simply Wall St. 2 months ago

COHR

ALNY

VRTX

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

0HD2.IL,0P0001H9AM,281 (0HD2.IL)

High Growth Tech Stocks In US With Potential For Expansion

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025

Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision

Alnylam price target raised to $338 from $300 at Scotiabank

Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio

Alnylam Stock Jumps After the FDA Approves Its Heart Drug

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

Dr. Phillip A. Sharp Retirement From Alnylam Pharmaceuticals (NasdaqGS:ALNY) Board Announced

High Growth Tech Stocks Leading The US Market

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

Alnylam Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results

Exploring Three High Growth Tech Stocks In The United States